The Capital Region of Denmark (Region Hovedstaden) has now given official approval to Asarina Pharma to begin its phase IIa study in Tourette, following a four-month delay due to an administrative backlog. The phase IIa Tourette study will take place at the Danish National Center for Tourette at Herlev University Hospital, Scandinavia's largest Tourette department, and Bispebjerg University hospital. 30 patients ranging from 12 to 45 years old will be included in the study. There is an acute un-met need for a safe and effective pharmaceutical treatment of Tourette. Current treatments like haloperidol (Haldol) reduce tics but involve severe side effects. Asarina Pharma's compound Sepranolonereduced tics as effectively as Haldol but without inducing any motor side effects in preclinical studies in 2019. Data from an additional animal model confirmed the initial findings in February 2021.